Dr Javier Cortés speaks to ecancer about the phase 3 ASCENT-03 trial that evaluated sacituzumab govitecan (SG) versus standard chemotherapy as first-line treatment in patients with locally advanced unresectable or metastatic triple-negative breast cancer (mTNBC) who could not receive PD-(L)1 inhibitors.

A total of 558 patients were randomised, and after a median follow-up of 13.2 months, SG demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a median PFS of 9.7 months compared to 6.9 months with chemotherapy (HR 0.62; P < .0001).

Dr Cortés says that the responses were also more durable with SG, with a median duration of response of 12.2 months versus 7.2 months. He highlights that these results support SG as a potential new standard of care for first-line mTNBC patients who are ineligible for PD-(L)1 therapy.